Nkarta (NKTX) Non-Current Assets (2019 - 2026)
Nkarta (NKTX) posted quarterly Non-Current Assets of $136.2 million for Q1 2026, down 31.58% year-over-year from $199.1 million in Q1 2025, and up 11.91% quarter-over-quarter from $121.7 million in Q4 2025.
Nkarta (NKTX) Non-Current Assets (2019 - 2026) Analysis & Trends
Nkarta's Non-Current Assets history runs 8 years deep, the most recent figure standing at $136.2 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 31.58% year-over-year to $136.2 million; the TTM figure through Mar 2026 stood at $547.6 million (down 38.55% YoY), while the FY2025 annual figure was $121.7 million, down 46.59% from the prior year.
- Non-Current Assets for Q1 2026 stood at $136.2 million, up from $121.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $241.9 million in Q3 2024, with the low at $83.1 million in Q1 2022.
- The 5-year median for Non-Current Assets is $134.2 million (2024), against an average of $145.7 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets surged 299.14% in 2022, then sank 46.59% in 2025.
- Nkarta's Non-Current Assets stood at $112.2 million in 2022, then advanced by 12.08% to $125.8 million in 2023, then jumped by 81.11% to $227.9 million in 2024, then plunged by 46.59% to $121.7 million in 2025, then gained by 11.91% to $136.2 million in 2026.
- Business Quant data shows NKTX's Non-Current Assets at $136.2 million in Q1 2026, $121.7 million in Q4 2025, and $138.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 18.06 Bn |
| 10 | Nkarta | 197.41 Mn | 197.41 Mn | - | 149.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 149.60 Mn |
| Mar 31, 2026 | 136.19 Mn |
| Dec 31, 2025 | 121.70 Mn |
| Sep 30, 2025 | 137.96 Mn |
| Jun 30, 2025 | 151.74 Mn |
| Mar 31, 2025 | 199.06 Mn |
| Dec 31, 2024 | 227.87 Mn |
| Sep 30, 2024 | 241.88 Mn |
| Jun 30, 2024 | 222.29 Mn |
| Mar 31, 2024 | 134.16 Mn |
| Dec 31, 2023 | 125.81 Mn |
| Sep 30, 2023 | 124.68 Mn |
| Jun 30, 2023 | 142.30 Mn |
| Mar 31, 2023 | 125.98 Mn |
| Dec 31, 2022 | 112.25 Mn |
| Sep 30, 2022 | 102.88 Mn |
| Jun 30, 2022 | 86.26 Mn |
| Mar 31, 2022 | 83.08 Mn |
| Dec 31, 2021 | 28.12 Mn |
| Sep 30, 2021 | 27.83 Mn |